Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT

In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). A total of 30 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Farnebo, Jacob, Wadelius, Agnes, Sandström, Per, Nilsson, Sten, Jacobsson, Hans, Blomqvist, Lennart, Ullén, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979788/
https://www.ncbi.nlm.nih.gov/pubmed/27495034
http://dx.doi.org/10.1097/MD.0000000000004308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979788/
https://www.ncbi.nlm.nih.gov/pubmed/27495034
http://dx.doi.org/10.1097/MD.0000000000004308

Ejemplares similares